诺灵生物医药科技

Nuoling Bio is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for oncology. The company leverages a proprietary polymer-based linker technology that enables high drug-to-antibody ratios (DAR) while maintaining excellent stability and solubility. Its lead candidate, NC-20, is a HER2-targeting ADC currently in Phase 1 clinical trials for solid tumors. Beyond HER2, the company is advancing a pipeline of ADCs targeting Trop2 and Claudin 18.2. Nuoling Bio aims to overcome the therapeutic window limitations of conventional ADCs to provide more effective treatments for cancer patients. The company is headquartered in Beijing and is supported by leading venture capital investors.